Bayer Concludes Patent License Agreement with Catalysis Manufacturer

Bayer MaterialScience is strengthening its position in developing new areas of application for carbon nanotubes (CNT). The company concluded a patent license agreement for the use of these materials with U.S. based company Hyperion Catalysis International, Inc.

The agreement will help to solidify the leading positions of both companies in research and development as well as production technology for high-quality CNT-based products. Financial terms were not disclosed.

"We see high demand for materials with extraordinary material properties," said Dr. Joachim Wolff, Member of the Executive Committee at Bayer MaterialScience. "Developments using Baytubes carbon nanotubes represent a key technology of the future for such requirements profile, and we are optimistic that we can offer our customers innovative and long-term solutions in these areas."

Baytubes carbon nanotubes can be used as additives in established materials such as plastics and metal. They are versatile due to their unique property profile - from enhanced electrical and thermal conductivity to exceptional mechanical load bearing capacity. Among other things, Baytubes CNT can help to increase endurance and efficiency of lithium-ion batteries, which in turn opens up their strong potential for use in energy-efficient electro-mobility concepts.

As one of the world's leading manufacturers of polymers and high-performance plastics, Bayer MaterialScience recognized the huge potential of nanotechnology early on. It has carried out intensive research into carbon nanotube production processes. Based in Cambridge, Massachusetts, U.S.A., Hyperion has been active in the field of carbon nanotubes since 1983 and currently holds a comprehensive portfolio of patents and patent applications covering a broad technology range, from CNT manufacturing to a variety of current and future applications.

David M. Wohlstadter, Hyperion's Vice President of Business Development stated, "We are quite pleased to have entered into this arrangement with Bayer MaterialScience. This license with BMS will further leverage Hyperion's broad patent portfolio and capitalize on the ever increasing demand for carbon nanotubes. We feel Bayer MaterialScience is well positioned to serve and help increase this demand, while Hyperion remains committed to expanding its own sales and providing its customers with the highest quality carbon nanotube based products."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Covestro AG. (2019, February 12). Bayer Concludes Patent License Agreement with Catalysis Manufacturer. AZoNano. Retrieved on March 05, 2024 from https://www.azonano.com/news.aspx?newsID=21922.

  • MLA

    Covestro AG. "Bayer Concludes Patent License Agreement with Catalysis Manufacturer". AZoNano. 05 March 2024. <https://www.azonano.com/news.aspx?newsID=21922>.

  • Chicago

    Covestro AG. "Bayer Concludes Patent License Agreement with Catalysis Manufacturer". AZoNano. https://www.azonano.com/news.aspx?newsID=21922. (accessed March 05, 2024).

  • Harvard

    Covestro AG. 2019. Bayer Concludes Patent License Agreement with Catalysis Manufacturer. AZoNano, viewed 05 March 2024, https://www.azonano.com/news.aspx?newsID=21922.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.